{"id":"NCT01411241","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers","officialTitle":"Immunogenicity and Safety of a Booster Injection of DTaP-IPV//Hib (Pentaxim™) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in Mexico","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-07-18","primaryCompletion":"2014-02-04","completion":"2014-04","firstPosted":"2011-08-08","resultsPosted":"2019-07-29","lastUpdate":"2022-03-25"},"enrollment":720,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Dengue","Dengue Hemorrhagic Fever"],"interventions":[{"type":"BIOLOGICAL","name":"Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus","otherNames":["CYD Dengue Vaccine"]},{"type":"BIOLOGICAL","name":"DTaP IPV//Hib vaccine","otherNames":["Pentaxim™"]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":["NaCl"]},{"type":"BIOLOGICAL","name":"Measles, mumps, and rubella vaccine","otherNames":["Trimovax®"]},{"type":"BIOLOGICAL","name":"Pneumococcal vaccine","otherNames":["Prevenar®"]},{"type":"BIOLOGICAL","name":"Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus","otherNames":["CYD Dengue Vaccine"]},{"type":"BIOLOGICAL","name":"DTaP IPV//Hib vaccine","otherNames":["Pentaxim™"]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":["NaCl"]},{"type":"BIOLOGICAL","name":"Measles, mumps, and rubella vaccine","otherNames":["Trimovax®"]},{"type":"BIOLOGICAL","name":"Pneumococcal vaccine","otherNames":["Prevenar®"]}],"arms":[{"label":"CYD Dengue Vaccine Group 1","type":"EXPERIMENTAL"},{"label":"CYD Dengue Vaccine Group 2","type":"EXPERIMENTAL"}],"summary":"The aim of the study was to assess whether the second CYD dengue vaccination could be administered concomitantly with the booster vaccination of a pediatric combination vaccine (Pentaxim™) during the same day visit but in 2 different sites of administration.\n\nPrimary Objective:\n\n* To demonstrate the non-inferiority of the antibody response against all antigens (diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b (Hib)) in participants receiving one booster dose of Pentaxim™ vaccine administered concomitantly with the second dose of CYD dengue vaccine compared to participants receiving one booster dose of Pentaxim™ vaccine administered concomitantly with placebo.\n\nSecondary Objectives:\n\n* To describe the safety of Pentaxim™ vaccine administered concomitantly with the second dose of CYD dengue vaccine, or administered concomitantly with placebo.\n* To describe the safety of the CYD dengue vaccine after the second dose of CYD dengue vaccine administered concomitantly with Pentaxim™ vaccine (at Visit 05) or administered alone (at Visit 06).\n* To describe the safety of the CYD dengue vaccine in all participants after each dose.\n* To describe the antibody response to each dengue virus serotype (post-Dose 2 and post-Dose 3) after the second dose of CYD dengue vaccine administered concomitantly with Pentaxim vaccine (at Visit 05) or administered alone (at Visit 06).\n* To describe the antibody response to each dengue virus serotype post-Dose 2 and post-Dose 3.","primaryOutcome":{"measure":"Percentage of Participants With Seroprotection or Booster Response After a Booster Injection (Inj.) of Diphtheria, Tetanus, Acellular Pertussis(DTaP)-Inactivated Polio Virus (IPV)//Hib (Pentaxim™) Administered Concomitantly With CYD Dengue Vaccine","timeFrame":"28 days post-injection","effectByArm":[{"arm":"CYD Dengue Vaccine Group 1","deltaMin":100,"sd":null},{"arm":"CYD Dengue Vaccine Group 2","deltaMin":100,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"9 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":15},"locations":{"siteCount":4,"countries":["Mexico"]},"refs":{"pmids":[],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":309},"commonTop":["Irritability; Post-injection 1","Crying abnormal; Post-injection 1","Nasopharyngitis","Appetite lost; Post-injection 1","Injection site Tenderness; Post-injection 1"]}}